Affinergy Inc.
This article was originally published in Start Up
Executive Summary
Affinergy has--patented and in the freezer--peptide binders that stick specifically to the common materials of which medical implants are made, for example, collagen, titanium and stainless steel. These are the starting point for the company's device coating platform. The other part of the biocoating, which attaches to the device-binding peptide by a linker, is a peptide that binds to a specific protein or cell type of interest to a partner.
You may also be interested in...
Biocoatings: Not Just the Icing on the Cake
The successful commercialization of drug-eluting stents (DES) has done much to pave the way for the biocoating industy. DES not only helped establish a new regulatory body to facilitate device-drug reviews, the FDA Office of Combination Products, they also proved that biocoated devices could take market share from uncoated products, command premium pricing and premium reimbursement.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.